Seelos Therapeutics, Inc. (NASDAQ:SEELQ) — Market Cap & Net Worth
Market Cap & Net Worth: Seelos Therapeutics, Inc. (SEELQ)
Seelos Therapeutics, Inc. (NASDAQ:SEELQ) has a market capitalization of $58.00 ($58.00) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31790 globally and #6299 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Seelos Therapeutics, Inc.'s stock price $0.00 by its total outstanding shares 581000 (581.00K). Review debt load of Seelos Therapeutics, Inc. to assess the company's total debt and financial obligations.
Seelos Therapeutics, Inc. Market Cap History: 2026 to 2026
Seelos Therapeutics, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $58.10 to $58.10 (0.00% CAGR).
Seelos Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Seelos Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SEELQ by Market Capitalization
Companies near Seelos Therapeutics, Inc. in the global market cap rankings as of June 18, 2026.
Key companies related to Seelos Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Seelos Therapeutics, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Seelos Therapeutics, Inc.'s market cap moved from $58.10 to $ 58.10, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $58.10 | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Seelos Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $58.00 USD |
| MoneyControl | $58.00 USD |
| MarketWatch | $58.00 USD |
| marketcap.company | $58.00 USD |
| Reuters | $58.00 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more